MicroRNAs in the control of metastatic bone disease

Standard

MicroRNAs in the control of metastatic bone disease. / Browne, Gillian; Taipaleenmäki, Hanna; Stein, Gary S; Stein, Janet L; Lian, Jane B.

In: TRENDS ENDOCRIN MET, Vol. 25, No. 6, 01.06.2014, p. 320-327.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Browne, G, Taipaleenmäki, H, Stein, GS, Stein, JL & Lian, JB 2014, 'MicroRNAs in the control of metastatic bone disease', TRENDS ENDOCRIN MET, vol. 25, no. 6, pp. 320-327. https://doi.org/10.1016/j.tem.2014.03.014

APA

Browne, G., Taipaleenmäki, H., Stein, G. S., Stein, J. L., & Lian, J. B. (2014). MicroRNAs in the control of metastatic bone disease. TRENDS ENDOCRIN MET, 25(6), 320-327. https://doi.org/10.1016/j.tem.2014.03.014

Vancouver

Browne G, Taipaleenmäki H, Stein GS, Stein JL, Lian JB. MicroRNAs in the control of metastatic bone disease. TRENDS ENDOCRIN MET. 2014 Jun 1;25(6):320-327. https://doi.org/10.1016/j.tem.2014.03.014

Bibtex

@article{39474d1c83754ec2914d102be3435456,
title = "MicroRNAs in the control of metastatic bone disease",
abstract = "Bone metastasis is a common and devastating complication of late-stage breast and prostate cancer. Complex interactions between tumor cells, bone cells, and a milieu of components in their microenvironment contribute to the osteolytic, osteoblastic, or mixed lesions present in patients with metastasis to bone. In the past decade microRNAs (miRNAs) have emerged as key players in cancer progression, but the importance of miRNAs in regulating cancer metastasis to bone is only now being appreciated. We emphasize here important concepts of bone biology and miRNAs in the context of breast and prostate cancer, and focus on recent advances that have improved our understanding of the role of specific miRNAs with direct involvement in metastatic bone disease.",
author = "Gillian Browne and Hanna Taipaleenm{\"a}ki and Stein, {Gary S} and Stein, {Janet L} and Lian, {Jane B}",
note = "Copyright {\textcopyright} 2014 Elsevier Ltd. All rights reserved.",
year = "2014",
month = jun,
day = "1",
doi = "10.1016/j.tem.2014.03.014",
language = "English",
volume = "25",
pages = "320--327",
journal = "TRENDS ENDOCRIN MET",
issn = "1043-2760",
publisher = "Elsevier Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - MicroRNAs in the control of metastatic bone disease

AU - Browne, Gillian

AU - Taipaleenmäki, Hanna

AU - Stein, Gary S

AU - Stein, Janet L

AU - Lian, Jane B

N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Bone metastasis is a common and devastating complication of late-stage breast and prostate cancer. Complex interactions between tumor cells, bone cells, and a milieu of components in their microenvironment contribute to the osteolytic, osteoblastic, or mixed lesions present in patients with metastasis to bone. In the past decade microRNAs (miRNAs) have emerged as key players in cancer progression, but the importance of miRNAs in regulating cancer metastasis to bone is only now being appreciated. We emphasize here important concepts of bone biology and miRNAs in the context of breast and prostate cancer, and focus on recent advances that have improved our understanding of the role of specific miRNAs with direct involvement in metastatic bone disease.

AB - Bone metastasis is a common and devastating complication of late-stage breast and prostate cancer. Complex interactions between tumor cells, bone cells, and a milieu of components in their microenvironment contribute to the osteolytic, osteoblastic, or mixed lesions present in patients with metastasis to bone. In the past decade microRNAs (miRNAs) have emerged as key players in cancer progression, but the importance of miRNAs in regulating cancer metastasis to bone is only now being appreciated. We emphasize here important concepts of bone biology and miRNAs in the context of breast and prostate cancer, and focus on recent advances that have improved our understanding of the role of specific miRNAs with direct involvement in metastatic bone disease.

U2 - 10.1016/j.tem.2014.03.014

DO - 10.1016/j.tem.2014.03.014

M3 - SCORING: Journal article

C2 - 24811921

VL - 25

SP - 320

EP - 327

JO - TRENDS ENDOCRIN MET

JF - TRENDS ENDOCRIN MET

SN - 1043-2760

IS - 6

ER -